Eli Lilly said its experimental weekly injection retatrutide helped adults with obesity or overweight and type 2 diabetes lose an average of up to 20.8% of their body weight over 80 weeks in the phase 3 TRIUMPH-2 trial. The company said Sept. 29 that the full results were presented at the European Association for the Study of Diabetes annual meeting in Milan and published in The Lancet.
According to Lilly, participants on 4 mg, 9 mg and 12 mg doses lost an average of 12.7%, 19.1% and 20.8% of their body weight, respectively, compared with 4.0% on placebo. Among participants who started with a body mass index of 35 or higher, those on 12 mg lost an average of 23.4%, the company said. Lilly said 52.0% of participants on 12 mg lost at least 20% of their body weight, compared with 1.5% on placebo.
Lilly said A1C, a measure of average blood sugar, fell by 1.4% on 4 mg, 1.6% on 9 mg and 1.5% on 12 mg, compared with 0.2% on placebo. The company said its figures use the efficacy estimand, which estimates results if all participants had stayed on treatment. Under the treatment-regimen estimand, mean weight loss was 11.9%, 16.8% and 18.8% on the three doses versus 5.1% on placebo, according to Healio (opens in new tab) and the European Association for the Study of Diabetes’ summary of the paper. The trial randomized 1,152 participants at 92 sites in eight countries, the association said.
The most common side effects were gastrointestinal. Lilly said diarrhea was reported by 27.4% to 33.6% of participants on retatrutide versus 13.2% on placebo, and nausea by 13.7% to 28.0% versus 8.0%. Discontinuation because of adverse events was 3.8% on 4 mg, 11.6% on 9 mg and 7.7% on 12 mg, compared with 4.9% on placebo, according to the company. The association’s summary said seven deaths occurred during the study and that all were judged unrelated to the study treatment.
Fierce Biotech (opens in new tab) wrote that the expanded data add to evidence that retatrutide has a more modest effect on blood sugar than on weight. It noted that up to 55.3% of patients on Lilly’s tirzepatide reached an A1C below 5.7% in an earlier trial, while Lilly reported up to 40.0% for retatrutide. Fierce also reported that TD Cowen analysts said early data for a rival triple agonist from Hengrui and Kailera “looks better.”
The study was sponsored by Lilly, the association said, and Healio (opens in new tab) reported that the trial had no direct comparator drug. Dr. Juan P. Frías, a study co-author who presented the study design and efficacy results, reports receiving research support from and consulting for Lilly, among other companies, according to Healio (opens in new tab). The investigators wrote that “further studies are required to determine whether these benefits translate to improvements in other obesity-related complications,” the association’s summary said.
Lilly said it plans to submit an application to the Food and Drug Administration in the first quarter of 2027. Retatrutide is investigational and cannot yet be legally sold.